Adalimumab treatment in Japanese patients with generalized pustular psoriasis: Results of an open-label phase 3 study-Reference-Cited by-同舟云学术

Adalimumab treatment in Japanese patients with generalized pustular psoriasis: Results of an open-label phase 3 study

Published:2018-10-10 Issue:12 Volume:45 Page:1371-1380
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:J Dermatol

Author:

Morita Akimichi¹^ORCID,Yamazaki Fumikazu²^ORCID,Matsuyama Takashi³,Takahashi Kenzo⁴,Arai Satoru⁵,Asahina Akihiko⁶^ORCID,Imafuku Shinichi⁷,Nakagawa Hidemi⁶,Hasegawa Yuichi⁸,Williams David⁹,Matsuda Naoto⁸,Kitamura Susumu⁸^ORCID

Affiliation:

1. Department of Geriatric and Environmental Dermatology; Nagoya City University Graduate School of Medical Sciences; Nagoya Japan

2. Department of Dermatology; Kansai Medical University; Osaka Japan

3. Department of Dermatology; Tokai University Hachioji Hospital; Tokyo Japan

4. Department of Dermatology; University of the Ryukyus; Okinawa Japan

5. St Luke's International Hospital; Tokyo Japan

6. Department of Dermatology; The Jikei University School of Medicine; Tokyo Japan

7. Department of Dermatology; Fukuoka University; Fukuoka Japan

8. AbbVie G.K.; Tokyo Japan

9. AbbVie Inc.; North Chicago Illinois USA

Funder

AbbVie

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1346-8138.14664/fullpdf

Reference24 articles.

1. Acute generalized pustular psoriasis, von Zumbusch type, treated in the burn unit. A review of clinical features and new therapeutics;Varman;Burns,2014

2. Epidemiological survey from 2009 to 2012 of psoriatic patients in Japanese Society for Psoriasis Research;Ito;J Dermatol,2018

3. Practice guidelines 2014 for generalized pustular psoriasis (GPP) [in Japanese];Terui;Jpn J Dermatol,2015

4. Eli Lilly Japan KK Torii Pharmaceutical Co., Ltd Eli Lilly Japan and Torii Pharmaceutical launch “Taltz ® Subcutaneous Injection 80 mg Auto-injector” and “Taltz ® Subcutaneous Injection 80 mg Syringe” humanized anti-human IL-17A monoclonal antibody product https://www.torii.co.jp/en/release/

5. Kyowa Hakko Kirin Co., Ltd LUMICEF ® approved in Japan http://www.kyowa-kirin.com/news_releases/

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search;Dermatology and Therapy;2024-08-01

2. New and Emerging Treatments for Generalized Pustular Psoriasis: Focus on IL-36 Receptor Inhibitors;Pharmaceutics;2024-07-06

3. Taiwanese Dermatological Association consensus recommendations for the diagnosis, treatment, and management of generalized pustular psoriasis;Dermatologica Sinica;2024-04

4. Psoriasis and Related Disorders;Rook's Textbook of Dermatology;2024-03-19

5. Therapeutic Potential of Spesolimab-Sbzo in the Management of Generalized Pustular Psoriasis Flares in Adults: Evidence to Date;Psoriasis: Targets and Therapy;2024-03